SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: SHR-1210+Albumin-bound paclitaxel + epirubicin
Sponsor: Henan Cancer Hospital